Medincell's Stock Drops 3.5% and Hits the Bottom of the SBF 120 After a Brief Peak
The biotech company from Montpellier falls sharply mid-morning, after leading the SBF 120 in the previous session. The stock sinks to the bottom of the broader index, significantly diverging from the well-oriented Parisian market. This movement extends the turbulence initiated by the publication of the annual accounts last week.
A Sharp Decline that Erases Tuesday's Rebound and Brings the Stock Below Its Three Moving Averages
Medincell's stock loses 3.49% to €25.44, down from €26.36 the day before. The stock is among the biggest losers in the SBF 120, while the broader index gains 0.13% and the CAC 40 advances by 0.22%. This movement largely cancels out the 3% gain achieved on Tuesday and brings the weekly decline to 9.21%, and 6.4% over a month.
The price falls below its three moving averages, with a gap of 5.11% below the MM20 at €26.81, indicating a short-term momentum break since the 13.5% drop following the publication of the annual accounts on June 17. The RSI at 50 remains neutral, but the support at €24.08 is approaching and will be the reference zone if the selling pressure continues.
Shift Towards Recurring Revenues Still Dominates Debate After Annual Accounts
Over 12 months, the stock is still up 48.77% and maintains a gain of 18.33% over three months, despite the recent downturn. The stock's trajectory follows the path of the annual accounts 2025/2026 published on June 17: Uzedy's royalties jumped 42% to €9.3 million, while the net loss widened to €31.3 million from €18.4 million a year earlier. During this announcement, the company highlighted the commercial launch of Olanzapine LAI expected in the fourth quarter of 2026 as the next growth driver, while warning that operating expenses would continue to rise to support expansion. The market continues to weigh the ramp-up in recurring revenues against the absence of exceptional items that had supported the previous year.
